APOB and fatty liver disease: Overall, treatment of PEG-BR in obese mice improved the hepatic steatosis potentially by utilizing fat for β-oxidation, increasing fatty acid uptake, reducing plasma ApoB-VLDL and triglycerides (Figure 8).